Latest Recruitment News

Racura Oncology has detailed how its lead drug candidate, (E,E)-bisantrene, silences the cancer-driving MYC gene by stabilising G-quadruplex DNA structures, providing critical preclinical validation ahead of ongoing clinical trials.

Metal Powder Works nearly doubled its powder revenue in Q1 2026 while maintaining strong margins, secured its first NATO defence contract under the UK Ministry of Defence’s Project TAMPA, and advanced its Next Gen powder production system on schedule.

Kaiser Reef reports promising drilling results and key infrastructure upgrades at its Maldon Gold Project, setting the stage for expanded exploration and production in Victoria’s historic gold district.

Firebrick Pharma secured regulatory approval for Nasodine Nasal Spray in Indonesia and launched Nasodine Throat Spray in Singapore and Fiji, while raising $1.5 million to fuel growth. The company aims to quadruple its product and market footprint within three years.

Invion Limited is broadening its non-melanoma skin cancer trial to include basal cell carcinoma patients following encouraging safety and efficacy data from squamous cell carcinoma cohorts, targeting the largest skin cancer segment.

Hiremii Limited has delivered its most profitable quarter yet, reporting record revenue and gross profit alongside its first positive adjusted EBITDA. The company also secured its first recurring SaaS contracts, marking a milestone in its shift towards a technology-driven workforce intelligence model.

Emyria has unveiled the Empax Global Partnership Program, a high-margin clinical delivery platform targeting international drug sponsors amid growing demand for psychedelic-assisted mental health treatments.

29Metals Limited (ASX:29M) swung to a $24 million net profit in 2025, powered by steady copper output at Golden Grove despite seismic disruptions, cost efficiencies, and key progress on growth projects including Gossan Valley and Capricorn Copper restart.

Dalaroo Metals has secured robust community and government backing ahead of its soil geochemistry program at the Bondoukou Gold Project in Côte d’Ivoire, with 40% of sampling now complete and assay results expected by early June 2026.

Nyrada has secured ethics approval to start its Phase IIa trial of Xolatryp in heart attack patients, with recruitment beginning in April 2026. The biotech also bolsters its cash position to AU$6.74 million and pursues new oncology indications.

Hiremii Limited has landed its initial paying customers for its AI-powered workforce intelligence platform, marking a pivotal step in its shift from recruitment services to a SaaS technology provider in energy and infrastructure sectors.

Entropy Neurodynamics has dosed its third patient with TRP-8803 in a Binge Eating Disorder trial, achieving a full and controlled psychedelic response that underscores the drug’s potential for precise therapeutic delivery.